This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidneydisease (CKD), and cardiovascular riskfactors, a prespecified.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidneydisease with additional cardiovascular riskfactors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.
Officially published by the AHA six months ago, CKM syndrome defines the connections and risks associated with obesity, type 2 diabetes, chronic kidneydisease, and cardiovascular disease. White) to assess their CKM stages, finding the following breakdown: Stage 0 (no riskfactors) – 10.6%
Diabetickidneydisease is an established riskfactor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
Background To assess the roles of diabetic microvascular disease and modifiable riskfactors and their combination in the development of arrhythmias. Methods We included participants with type 2 diabetes (T2D) who were free of arrhythmias during recruitment in the UK Biobank study.
BackgroundInhibition of prostaglandin synthesis by nonsteroidal anti‐inflammatory drugs is associated with cardiovascular mortality and kidneydisease. Longitudinal associations with cardiovascular mortality and kidney outcomes (eGFR <60 or <45 mL/min per 1.73 1.54]; PGEM HR, 1.36 [95% CI, 1.10–1.67]).
Participants with an RHR of ≥80 bpm had a higher stage of chronic kidneydisease, lower estimated glomerular filtration rate, and more proteinuria than those with an RHR of 60 to 69 bpm. 1.90]) higher risk of ESRD, respectively. The risk of ESRD remained significantly elevated (HR, 1.32 [95% CI, 1.10–1.58]
BackgroundStroke and dementia are leading causes of mortality and can be prevented through riskfactor management. Riskfactor assessment requires laboratory or physical measurements. Journal of the American Heart Association, Ahead of Print.
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular riskfactors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
This can be mitigated through targeting modifiable riskfactors. Identification of those at-risk through screening tools could be facilitated by inclusion of self-reported riskfactors rather than reliance on clinical data.
Here’s what you can expect at the biggest conference in cardiorenal metabolic health, the 19th Annual Cardiometabolic Congress (CMHC), DECODING THE CONSTELLATION of Cardiometabolic Health and RiskFactors. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular riskfactors in patients with hemophilia compared to the general population.
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidneydisease.”
Background:The ABCD-GENE score, incorporating age, body mass index, chronic kidneydisease, diabetes, and CYP2C19 genotypes, is a validated risk score that integrates clinical riskfactors with genetic information to predict clopidogrel response. The mean age of the participants was 64.4 years, with 65.0%
It’s well known that heart disease is the U.S.’s s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. trillion, representing 4.6% of US GDP.
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidneydisease, and cardiovascular disease. CKM syndrome stages 3 and 4 are considered advanced.
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among year follow-up time).Results:Among
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidneydisease.”
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. This ensures clear communication and identifies areas that need further explanation.
Themed “Decoding the Constellation of Cardiometabolic Health and RiskFactors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US. When I heard of his passing, I felt quite sad.
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
Logistic regression was used to determine the association between 5-HTP levels and calcification severity, adjusting for age, gender, smoking status, chronic kidneydisease, hyperlipidemia, and diabetes. For other factors, the OR for smokers was 0.97 (0.53 to 1.10); diabetes 1.24 (0.67 95% CI = 2.6 to 40686.5).
Implementation of a multispecialty care team approach, including expertise in riskfactor management, guideline directed medical therapies, wound and foot care and endovascular and surgical revascularization procedures, may improve outcomes for people with PAD. and Global Data From the American Heart Association.
Hypertension, diabetes, hyperlipidemia, and chronic kidneydisease are well-known cardiovascular riskfactors for ICH. However, the relationship between the polygenic profiles (PP) of these riskfactors and ICH risk in AF patients on anticoagulation remains unclear.
HTN accelerates the progression of atherosclerosis and leads to increased risk of major cardiac events like heart attack, heart failure, kidneydisease and other end organ damage. HTN is the leading global riskfactor for death, affecting an estimated 1.28 billion adults worldwide.
We examined trends in incidence, urgent dialysis, mortality, and its riskfactors using Poisson regression models. RESULTS:The median age of the patients was 76 years, and 54.9% were women. Urgent dialysis rates increased from 1.52% (95% CI, 1.12–2.06) 2.06) to 2.60% (2.17–3.1;
The prevalence of HF riskfactors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidneydisease; 22%. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
Barb, MD MASLD, MASH and diabetes To explain the important implications of metabolic diseases like type 2 diabetes in the pathophysiology of MASLD and MASH, Diana D. Multinational liver societies announce new “fatty” liver disease nomenclature that is affirmative and non-stigmatizing(no date) org. As of the Oct.
Riskfactors such as smoking, chronic kidneydisease, and aging can contribute to plaque formation. This study aims to assess the effect of aging on NaF uptake in the left common carotid artery (LCC) in subjects with known cardiovascular risk factors.MethodsIn total, 36 subjects (mean age 55.4 ± 12.3
“In addition to our new online hubs, we are continually designing live education for delivery as satellite symposia at other large conferences such as the American Heart Association or American Diabetes Association Scientific Sessions. ” Learners can see some of the CMHC experts in person on Aug.
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 mg) to reduce the risks of heart attack, stroke, coronary revascularization, and CV death.29
Further, the guideline sets forth a new way to classify AFib, using stages, that reinforces the continuum of the disease and underscores the need to use a variety of strategies at the different stages, including prevention, lifestyle and riskfactor modification, screening, and therapy.
The benefit of resistance training observed in observational studies is supported by controlled trials on resistance training, which demonstrate that this type of exercise reduces traditional and nontraditional CVD riskfactors. a higher metabolism). Aerobic training is probably best for increasing cardiorespiratory fitness (i.e.,
The benefit of resistance training observed in observational studies is supported by controlled trials on resistance training, which demonstrate that this type of exercise reduces traditional and nontraditional CVD riskfactors. a higher metabolism). Aerobic training is probably best for increasing cardiorespiratory fitness (i.e.,
Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major riskfactor for cardiometabolic disease. 5, 6] So, it seems that once cardiovascular disease is present, then obesity may offer some degree of protection. This benefit is less pronounced in patients with class II obesity (BMI 35 to 39.9
CABANA Trial randomized 2204 patients with AF aged 65 years or more and those below 65 years with one or more riskfactors for stroke for catheter ablation with pulmonary vein ablation or drug therapy with rate or rhythm control. Among the subjects of CABANA trial 35% had NYHA class above II at baseline.
Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidneydisease (CKD) commonly coexist. Compared with CKD and T2D, those with CKD and HF and HF and T2D had more severe riskfactor profile. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.
Background Chronic kidneydisease (CKD) and atrial fibrillation (AF) are increasing in prevalence globally and share common riskfactors. Age, sex, diabetes, hypertension and heart failure were chosen as variables of interest. Methods PubMed, EMBASE and CINAHL were searched from inception to June 2022.
Introduction:Chronic kidneydisease (CKD) is a riskfactor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. For each patient, eGFR along with age, sex, race, ethnicity, hypertension, diabetes (DM), heart disease, and hyperlipidemia were abstracted.
We compared these factors among patients who were readmitted within 90‐days post initial stroke admission to those who were not admitted to identify riskfactors for readmissionResultsAmong the 200,058 patients discharged following an ischemic stroke in 2018, 25.9% (n=51,860) had an all‐cause 90‐day readmission. female and 83.1%
Background:Research suggests that residing in a food desert (FD) area may negatively impact health by increasing cardiovascular riskfactors. This study aims to assess sociodemographic profile and stroke riskfactors among individuals residing in FDs within the predominantly rural state of South Carolina (SC).Methods:Deidentified
Introduction:Chronic kidneydisease (CKD) is a riskfactor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. For each patient, eGFR (estimated glomerular filtration rate) along with age, sex, race, ethnicity, hypertension (HTN), diabetes (DM), heart disease, and hyperlipidemia were abstracted.
Few studies, however, have investigated the risk of CTO in individuals with HU and the role of traditional cardiovascular riskfactors in this setting. Methods A cohort of 1245 individuals without chronic kidneydisease from southwest China who underwent coronary angiography between February 2018 and June 2021 were enrolled.
While the reasons for this increase are multifactorial, there is likely a contribution from the known rise in traditional vascular riskfactors (VRFs) among the general young adult population. VRFs included hypertension, diabetes, kidneydisease, smoking, drug or alcohol abuse, antithrombotic medication use, and sleep apnea.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content